Yearly Archives - 2016

‘He loves them’: Special e-specs give blind boy a new lease on life

It's a big day for Benny Francey. He's at the library in Selkirk, Man. for the first time with new specs. "I can actually see complete detail," Benny, 10, says. The boy and his brother are living with a rare disease called Leber congenital amaurosis. The condition means the boys can only see silhouette-like images. The specs inside the case are eSight glasses from a startup in Toronto and cost $20,000 Canadian dollars — a hefty bill that was paid for by a GoFundMe campaign...
Read more...

Hoping to see again, local woman seeks funds for $15,000 device

Three months ago, Donna Witcher, who is legally blind, walked outside her Torresdale home and identified a stop sign. "It was amazing," said Witcher, a buoyant 52-year-old. "I could actually see." The secret to her sudden vision? A high-tech headset called eSight, which employs a tiny camera that sends high-resolution video through a computer and back to small LED screens in front of the viewer's eyes. Read more >>
Read more...

Community raises $15K to help legally blind Independence boy see

Thanks to the community, a young boy is going to be able to see better than ever. Corbin Wolfe’s family raised the $15,000 they needed for his eSight eyewear. They’ve ordered it, and it’s on its way. All of Kansas City fell in love with 7-year-old after they saw a video of him trying on eSight for the very first time. It’s new technology using a camera and monitor to help people who are legally blind see. Read more >>
Read more...

Two Biotech Stocks Are Just So Hot Right Now (Corbus Pharmaceuticals Holdings, Inc.)

On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. Read more >>
Read more...

Myomo Wants to Help Brain Injury Survivors Overcome Paralysis

For those who experience a stroke or traumatic brain injury, some are left with having to cope and adapt to having a paralyzed or weak limb. According to Cleveland Clinic, patients who have a left-brain stroke may experience paralysis on the right side of their body. Also, as stated by the National Stroke Association, as many as 9 out of 10 stroke survivors have some degree of paralysis immediately following a stroke. Myomo, a medtech company, is working to empower...
Read more...

The Angel Investor Portfolio

The following post is from Antonette Ho, Group Operations Manager at Boston Harbor Angels. Original post can be found here >> Boston Harbor Angels I recently had the privilege to attend an Angel Portfolio Workshop, hosted by the Boston Harbor Angels, one of the top angel groups in the country. Attendees were members of the Boston Harbor Angels who had diverse portfolios and a variety of experiences as angel investors. It was a lively discussion where participants shared best practices based on their...
Read more...